Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Keratitis-Ichthyosis-Deafness Syndrome: Phenotypic Heterogeneity and Treatment Perspective of Patients With P.Asp50asn Gjb2 Mutation Publisher Pubmed



Asgari T1 ; Naji M2, 3 ; Mansouri P4 ; Mahmoudi H5 ; Zabihi M6 ; Youssefian L2, 3 ; Mahdavi M7 ; Naraghi ZS8 ; Zeinali S6, 9 ; Vahidnezhad H2, 3 ; Uitto J2, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Biology, Science, and Research Branch, Islamic Azad University, Tehran, Iran
  2. 2. Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States
  3. 3. Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, United States
  4. 4. Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Dermatology, Tehran University of Medical Sciences, Razi Hospital, Tehran, Iran
  6. 6. Kawsar Human Genetics Research Center, Tehran, Iran
  7. 7. Thalassemia Research Center, Mazandaran University of Medical Sciences, Sari, Iran
  8. 8. Departments of Dermatology and Pathology, Tehran University of Medical Sciences, Razi Hospital, Tehran, Iran
  9. 9. Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Source: Dermatologic Therapy Published:2020


Abstract

Keratitis-ichthyosis-deafness (KID) syndrome is caused by mutations in the GJB2 gene encoding connexin 26, a component of transmembrane hemichannels which form gap junction channels, critical for cell-cell communication. Here, we report two patients from two distinct families with KID syndrome with the same GJB2 mutation (p.Asp50Asn); in both cases the mutation was de novo, as the parents depicted the wild-type allele only. The patients' cutaneous manifestations were strikingly different illustrating the wide spectrum of phenotype of these patients, even with the same GJB2 mutation. One of the patients was treated with acitretin with dramatic improvement in his skin findings, illustrating the role of oral acitretin in treatment of patients with KID syndrome. Collectively, these patients attest to the phenotypic spectrum of KID syndrome, with therapeutic perspective. © 2020 Wiley Periodicals LLC.